BioSpace News Archive

NewAmsterdam Pharma Company N.V. announced the closing of the previously announced underwritten public offering of 15,787,695 of the Company’s ordinary shares, with a nominal value of €0.12 per share by certain of the Company’s existing shareholders, including affiliates of Forbion, at a public offering price of $11.50 per share.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS) presented today updated clinical and translational data on its clinical trial BALLI-01 (evaluating UCART22) at the European Hematology Association (EHA) 2023.

Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate substantial target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities (DLTs) observed.

Affimed N.V. announced that two abstracts have been accepted for presentation at the 17th International Conference on Malignant Lymphoma taking place in Lugano, Switzerland on June 13-17, 2023.

Mirum Pharmaceuticals, Inc. announced that on June 9, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 43,150 shares of common stock and 22,030 restricted stock units to nine new employees under Mirum’s 2020 Inducement Plan.

UroGen Pharma Ltd. today announced the grants of inducement restricted stock units (“RSUs”) to 6 new employees in connection with their employment with UroGen.

TPG and AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of their previously announced acquisition of OneOncology, a network of leading oncology practices.

Marius Pharmaceuticals announced that its U.S. patents related to KYZATREX™, No. 11590146B2 and No. 11617758B2, are now listed in the U.S. Food and Drug Administration publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the “Orange Book.”.

Apex Labs Ltd. (APEX or the Company) announces Health Canada Approval of the company’s secondary US-based supplier of Good Manufacturing Practices (GMP) psilocybin Active Pharmaceutical Ingredient (API) in addition to its existing primary Canadian-based supplier.

Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced that it has received FDA approval for its generic version of Precedex®, Dexmedetomidine Hydrochloride Injection 4mcg/ml in 50mL and 100mL, and plans to launch in the very near future.